

Pharmasset Inc  
Form 8-K  
July 12, 2007

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 12, 2007**

---

**PHARMASSET, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

**Delaware**  
(State or Other Jurisdiction

**001-33428**  
(Commission File Number)

**98-0406340**  
(IRS Employer

of Incorporation)

Identification No.)

**303-A College Road East**

**Princeton, NJ**  
(Address of Principal Executive Offices)

**08540**  
(Zip Code)

**Registrant's telephone number, including area code: (609) 613-4100**

(Former Name or Former Address, if Changed Since Last Report.)

## Edgar Filing: Pharmasset Inc - Form 8-K

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events.**

On July 12, 2007, Pharmasset, Inc. issued a press release announcing the start of long-term chronic toxicology studies in two animal species as part of their collaboration with Roche for the development of R7128 for the treatment of hepatitis C virus (HCV). Roche triggered a \$7.5 million milestone payment to Pharmasset by initiating these studies. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release, dated July 12, 2007.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMASSET, INC.

Date: July 12, 2007

By: /s/ KURT LEUTZINGER

Name: Kurt Leutzinger

Title: Executive Vice President and Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit**

<b>Number</b>	<b>Description of Exhibit</b>
99.1	Press Release dated July 12, 2007.